Fig. 5
From: Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma
Western Blot and immunohistochemical assay. a CD47 immunohistochemical staining in gliomas of tumor bearing mice in group 1–8. b Western blot-based quantifications of expression of the CD47 in group 1–9. c CRT immunohistochemical staining in gliomas of tumor bearing mice in group 1–8. d Western blot-based quantifications of expression of the CRT in group 1–9. e Nestin immunohistochemical staining in gliomas of tumor bearing mice in group 1–8. f Western blot-based quantifications of expression of the Nestin in group 1–9. g CD133 immunohistochemical staining in gliomas of tumor bearing mice in group 1–8. h Western blot-based quantifications of expression of the CD133 in group 1–9. The results of western-blot are expressed as mean ± SD (n = 3). Group 1–9 correspond to the DOX-CB@lipo-iRGD-in situ-N (+) group, the DOX-CB@lipo-pDNA-iRGD-in situ-N (+) group, the DOX-CB@lipo-iRGD-iv-N (+) group, the lipo-pDNA-iRGD-in situ-N (+) group, the DOX + CB@lipo-iRGD-iv-N (+) group, the BSH-N (+), the N (+) group, the N (−) group, and the Sham group. Group 1–8 correspond to the DOX-CB@lipo-iRGD-in situ-N (+) group, the DOX-CB@lipo-pDNA-iRGD-in situ-N (+) group, the DOX-CB@lipo-iRGD-iv-N (+) group, the lipo-pDNA-iRGD-in situ-N (+) group, the DOX + CB@lipo-iRGD-iv-N (+) group, the BSH-N (+), the N (+) group, and the N (−) group